Director, Regulatory Affairs - Global Labeling
Gilead SciencesFull Time
Expert & Leadership (9+ years)
The Senior Manager, Global Clinical Regulatory Leader must have experience in providing strategic and operational direction for regulatory activities for drug products, including support for global clinical trials, regional registrations, and life cycle management. The role requires collaboration with regulatory affairs strategy teams and cross-functional teams, oversight of IND submissions in the US, and support for clinical trials applications globally. Experience in preparing and reviewing regulatory submissions such as RPDD, ODD, Annual Reports, DSURs, Scientific Advice briefing books, pre-IND, IND, Briefing Books, and MAA/BLA/NDAs is necessary. The position also requires maintaining current knowledge of relevant regulations and guidance, and liaising with CROs and internal teams for international health authority submissions.
The Senior Manager, Global Clinical Regulatory Leader is responsible for providing strategic and operational direction for regulatory activities of drug products, supporting global clinical trials, regional registrations, and life cycle management. This role involves collaborating with project teams and stakeholders for local product registrations, ensuring compliance with local regulatory requirements and commercial objectives, and providing regulatory support to Global Pharmacovigilance. Key duties include preparing global regulatory strategies, maintaining knowledge of regulations, analyzing development work within global regulatory guidance, preparing CCDS, US-PI, and SmPC documents, and preparing/reviewing various regulatory submissions. Additionally, the role involves initiating and executing CTA/CTNs in the US, EU, and globally, and managing interactions with health authorities and CROs.
Develops therapies for CNS disorders
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.